RxSight prices $100M public stock offering at $56/share for commercial expansion

RxSight, Inc.

Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.
Net proceeds expected ~$93.2M after underwriting discount and estimated offering expenses.
Proceeds to fund commercial/marketing expansion (including international), product development, R&D, and working capital.
Offering expected to close May 13, 2024, subject to customary closing conditions.
Directors and executive officers subject to 60-day lock-up restrictions on their shares.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the "Underwriters") valued at approximately $93.2 million (effective 2024-05-08).

Action: entry
Agreement: underwriting
Counterparty: BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the "Underwriters")
Value: approximately $93.2 million
Effective: 2024-05-08

Exact text from the filing

On May 8, 2024, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 1,785,714 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-135328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.